Hypercholesterolemia Pipeline Review, H1 2018 with Key Player Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Hypercholesterolemia - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 4, 1, 17, 5 and 3 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 6 molecules, respectively.
Key Topics CoveredIntroduction Hypercholesterolemia - Overview Hypercholesterolemia - Therapeutics Development Hypercholesterolemia - Therapeutics Assessment Hypercholesterolemia - Companies Involved in Therapeutics Development Hypercholesterolemia - Drug Profiles Hypercholesterolemia - Dormant Projects Hypercholesterolemia - Discontinued Products Hypercholesterolemia - Product Development Milestones Appendix
Companies MentionedAFFiRiS AG Akcea Therapeutics Inc AstraZeneca Plc BioLingus AG Catabasis Pharmaceuticals Inc Chong Kun Dang Pharmaceutical Corp CymaBay Therapeutics Inc Daewon Pharm Co Ltd Daewoong Co Ltd Dicerna Pharmaceuticals Inc Dybly AG Esperion Therapeutics Inc Gemphire Therapeutics Inc Golden Biotechnology Corp Immune Response BioPharma Inc Innovent Biologics Inc Kadmon Corp LLC Kyorin Pharmaceutical Co Ltd Leading BioSciences Inc LipimetiX Development Inc Madrigal Pharmaceuticals Inc Medlab Clinical Ltd Noxopharm Ltd Pfizer Inc Portola Pharmaceuticals Inc Progenra Inc Regeneron Pharmaceuticals Inc RegenxBio Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shenzhen HighTide Biopharmaceutical Ltd The Medicines Company Viking Therapeutics Inc Zhejiang Hisun Pharmaceutical Co Ltd
For more information about this report visit https://www.researchandmarkets.com/research/lkk5lx/hypercholesterolem?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005761/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/12/2018 07:18 AM/DISC: 06/12/2018 07:18 AM